OncoMatch/Clinical Trials/NCT05490719
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Is NCT05490719 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies QL1706 for esophageal squamous cell carcinoma.
Treatment: QL1706 — This is a single arm, multi-center Phase II Study. This clinical study is an investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the efficacy and safety of Chemoradiationtherapy combined with QL1706 (anti-CTLA-4 and PD-1 antibody) in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage II, III, IVA
Prior therapy
Cannot have received: esophageal cancer surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify